At Perrigo Company, people are driven by a challenge: to provide the world with affordable health care products. To meet this challenge, the company is developing generic prescription and OTC pharmaceuticals that provide value to patients without compromising quality.
The company has a rich history in consumer health care that dates back to the late nineteenth century, when the L Perrigo Company began packaging and distributing patented medicines and household items for country stores. The company then developed the private-label concept as a way to build customer loyalty; for no additional charge, Perrigo offered to imprint the individual store's name on the product labels for assorted goods stocked in general stores of that era, helping to establish the practice of store branding.
Perrigo's entrance into the generic prescription market is relatively new, however. In 2005, the company expanded its presence by acquiring Agis Industries Ltd, including its subsidiary, Clay-Park Labs. In 2007, Perrigo purchased an assortment of topical products from Glades Pharmaceuticals. The resulting portfolio for the Rx division focuses on formulations such as creams, ointments, gels, lotions, solutions, suspensions, suppositories, enemas, and nasal sprays. By investing heavily in new product development and acquisitions, Perrigo has taken a leadership position within the topical generic space.
The company also has a proven track record of being first to market with prescription-to-OTC products. This expertise has solidified the consumer healthcare division's position as the world's largest manufacturer of OTC pharmaceutical products for the store-brand market. It also has presented a unique distribution opportunity within the pharmacy called "ORx"?OTC pharmaceuticals available for pharmacy fulfillment and health care reimbursement when prescribed by a physician. Cetirizine hydrochloride tablets 10 mg and omeprazole delayed-release tablets 20 mg are the first 2 items available under this flag. This initiative takes advantage of synergies within the company. It also reaffirms Perrigo's commitment to finding new and creative ways to increase value for its customers and, ultimately, the patients.
Headquartered in Allegan, Michigan, Perrigo has operations in 7 countries, nearly 6000 employees, and annual sales of over $1.7 billion. Its real strength, however, comes from a talented and dedicated workforce that leverages its expertise in every endeavor.
For more information, visit Perrigo Company's Web site at www.perrigo.com, or call 866-634-9120.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs